Seeking Alpha

GlaxoSmithKline (GSK +0.4%) says it's submitted a regulatory application in the European Union...

GlaxoSmithKline (GSK +0.4%) says it's submitted a regulatory application in the European Union for umeclidinium bromide, or UMEC, an investigational once-daily medicine for patients with chronic obstructive pulmonary disease. Regulatory filings are pending in the U.S. and planned for other countries during the course of 2013.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector